Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: Evidence from in vitro and animal-based studies

Stuart J. Warden, Elizabeth Haney

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The regulation of bone metabolism continues to be an area of intense investigation, with recent evidence indicating a potential contribution from the neural system. In particular, the neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has been hypothesized to play a role in skeletal metabolism via its transporter (5-HTT). The 5-HTT is a plasma membrane transporter that is highly specific for the uptake of extracellular 5-HT, thereby facilitating the intracellular storage and/ or degradation of 5-HT. The 5-HTT is clinically important as it is the key target of pharmaceutical agents aimed at treating affective disorders, such as major depressive disorder. By antagonizing the 5-HTT, selective serotonin reuptake inhibitors (SSRIs) potentiate 5-HT activity and effectively relieve the symptoms of depression. However, questions have been raised regarding the potential skeletal effects of SSRIs given the recent identification of a functional 5-HTT and functional 5-HT receptors in bone cells. This paper discusses the preclinical evidence for the skeletal effects of 5-HT and the inhibition of the 5-HTT. In particular, it discusses the: (1) role of 5-HT and the function of the 5-HTT; (2) presence of functional 5-HTTs in bone; (3) potential sources and response mechanisms for 5-HT in bone, and; (4) in vitro and in vivo skeletal effects of 5-HT and 5-HTT inhibition.

Original languageEnglish (US)
Pages (from-to)121-132
Number of pages12
JournalJournal of Musculoskeletal Neuronal Interactions
Volume8
Issue number2
StatePublished - Jun 2008

Fingerprint

Serotonin
Bone and Bones
Serotonin Uptake Inhibitors
In Vitro Techniques
Inhibition (Psychology)
Membrane Transport Proteins
Serotonin Receptors
Major Depressive Disorder
Mood Disorders
Neurotransmitter Agents
Cell Membrane
Depression
Pharmaceutical Preparations

Keywords

  • Antidepressants
  • Fluoxetine
  • Neurotransmitter
  • Osteoporosis
  • Prozac

ASJC Scopus subject areas

  • Neuroscience(all)
  • Endocrinology

Cite this

@article{32f80b529bbc4a49a91d8f86f97b36bf,
title = "Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: Evidence from in vitro and animal-based studies",
abstract = "The regulation of bone metabolism continues to be an area of intense investigation, with recent evidence indicating a potential contribution from the neural system. In particular, the neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has been hypothesized to play a role in skeletal metabolism via its transporter (5-HTT). The 5-HTT is a plasma membrane transporter that is highly specific for the uptake of extracellular 5-HT, thereby facilitating the intracellular storage and/ or degradation of 5-HT. The 5-HTT is clinically important as it is the key target of pharmaceutical agents aimed at treating affective disorders, such as major depressive disorder. By antagonizing the 5-HTT, selective serotonin reuptake inhibitors (SSRIs) potentiate 5-HT activity and effectively relieve the symptoms of depression. However, questions have been raised regarding the potential skeletal effects of SSRIs given the recent identification of a functional 5-HTT and functional 5-HT receptors in bone cells. This paper discusses the preclinical evidence for the skeletal effects of 5-HT and the inhibition of the 5-HTT. In particular, it discusses the: (1) role of 5-HT and the function of the 5-HTT; (2) presence of functional 5-HTTs in bone; (3) potential sources and response mechanisms for 5-HT in bone, and; (4) in vitro and in vivo skeletal effects of 5-HT and 5-HTT inhibition.",
keywords = "Antidepressants, Fluoxetine, Neurotransmitter, Osteoporosis, Prozac",
author = "Warden, {Stuart J.} and Elizabeth Haney",
year = "2008",
month = "6",
language = "English (US)",
volume = "8",
pages = "121--132",
journal = "Journal of Musculoskeletal Neuronal Interactions",
issn = "1108-7161",
publisher = "International Society of Musculoskeletal and Neuronal Interactions",
number = "2",

}

TY - JOUR

T1 - Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition

T2 - Evidence from in vitro and animal-based studies

AU - Warden, Stuart J.

AU - Haney, Elizabeth

PY - 2008/6

Y1 - 2008/6

N2 - The regulation of bone metabolism continues to be an area of intense investigation, with recent evidence indicating a potential contribution from the neural system. In particular, the neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has been hypothesized to play a role in skeletal metabolism via its transporter (5-HTT). The 5-HTT is a plasma membrane transporter that is highly specific for the uptake of extracellular 5-HT, thereby facilitating the intracellular storage and/ or degradation of 5-HT. The 5-HTT is clinically important as it is the key target of pharmaceutical agents aimed at treating affective disorders, such as major depressive disorder. By antagonizing the 5-HTT, selective serotonin reuptake inhibitors (SSRIs) potentiate 5-HT activity and effectively relieve the symptoms of depression. However, questions have been raised regarding the potential skeletal effects of SSRIs given the recent identification of a functional 5-HTT and functional 5-HT receptors in bone cells. This paper discusses the preclinical evidence for the skeletal effects of 5-HT and the inhibition of the 5-HTT. In particular, it discusses the: (1) role of 5-HT and the function of the 5-HTT; (2) presence of functional 5-HTTs in bone; (3) potential sources and response mechanisms for 5-HT in bone, and; (4) in vitro and in vivo skeletal effects of 5-HT and 5-HTT inhibition.

AB - The regulation of bone metabolism continues to be an area of intense investigation, with recent evidence indicating a potential contribution from the neural system. In particular, the neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has been hypothesized to play a role in skeletal metabolism via its transporter (5-HTT). The 5-HTT is a plasma membrane transporter that is highly specific for the uptake of extracellular 5-HT, thereby facilitating the intracellular storage and/ or degradation of 5-HT. The 5-HTT is clinically important as it is the key target of pharmaceutical agents aimed at treating affective disorders, such as major depressive disorder. By antagonizing the 5-HTT, selective serotonin reuptake inhibitors (SSRIs) potentiate 5-HT activity and effectively relieve the symptoms of depression. However, questions have been raised regarding the potential skeletal effects of SSRIs given the recent identification of a functional 5-HTT and functional 5-HT receptors in bone cells. This paper discusses the preclinical evidence for the skeletal effects of 5-HT and the inhibition of the 5-HTT. In particular, it discusses the: (1) role of 5-HT and the function of the 5-HTT; (2) presence of functional 5-HTTs in bone; (3) potential sources and response mechanisms for 5-HT in bone, and; (4) in vitro and in vivo skeletal effects of 5-HT and 5-HTT inhibition.

KW - Antidepressants

KW - Fluoxetine

KW - Neurotransmitter

KW - Osteoporosis

KW - Prozac

UR - http://www.scopus.com/inward/record.url?scp=51749112868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51749112868&partnerID=8YFLogxK

M3 - Article

C2 - 18622081

AN - SCOPUS:51749112868

VL - 8

SP - 121

EP - 132

JO - Journal of Musculoskeletal Neuronal Interactions

JF - Journal of Musculoskeletal Neuronal Interactions

SN - 1108-7161

IS - 2

ER -